KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Palvella Therapeutics (PVLA) EPS (Weighted Average and Diluted): 2020-2024

Historic EPS (Weighted Average and Diluted) for Palvella Therapeutics (PVLA) over the last 4 years, with Dec 2024 value amounting to $0.12.

  • Palvella Therapeutics' EPS (Weighted Average and Diluted) fell 99.41% to $0.12 in Q4 2024 from the same period last year, while for Dec 2024 it was -$7.83, marking a year-over-year decrease of 652.88%. This contributed to the annual value of -$7.83 for FY2024, which is 460.83% down from last year.
  • Latest data reveals that Palvella Therapeutics reported EPS (Weighted Average and Diluted) of $0.12 as of Q4 2024, which was up 103.05% from -$3.94 recorded in Q3 2024.
  • Palvella Therapeutics' 5-year EPS (Weighted Average and Diluted) high stood at $20.50 for Q4 2023, and its period low was -$12.70 during Q2 2023.
  • Moreover, its 3-year median value for EPS (Weighted Average and Diluted) was -$1.54 (2024), whereas its average is -$0.99.
  • In the last 5 years, Palvella Therapeutics' EPS (Weighted Average and Diluted) slumped by 8,971.43% in 2023 and then skyrocketed by 80.55% in 2024.
  • Palvella Therapeutics' EPS (Weighted Average and Diluted) (Quarterly) stood at -$0.26 in 2020, then soared by 50.00% to -$0.13 in 2021, then skyrocketed by 44.00% to -$0.14 in 2022, then slumped by 8,971.43% to $20.50 in 2023, then crashed by 99.41% to $0.12 in 2024.
  • Its last three reported values are $0.12 in Q4 2024, -$3.94 for Q3 2024, and -$2.47 during Q2 2024.